Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer.Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin, American Medical Association. It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.
This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma,Clinical trials for SGN-75 "Clinicaltrials.gov" but development was discontinued in 2013.Seattle Genetics Third Quarter 2013 Financial Report No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.
References